Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Cash from Operating Activities
Adaptimmune Therapeutics PLC
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Cash from Operating Activities
-$140.9m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Operating Activities
-$160.3m
|
CAGR 3-Years
-147%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Operating Activities
-$145.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Operating Activities
-$60.6m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Operating Activities
£2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Cash from Operating Activities
£44.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is Adaptimmune Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-140.9m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Cash from Operating Activities amounts to -140.9m USD.
What is Adaptimmune Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-6%
Over the last year, the Cash from Operating Activities growth was 1%. The average annual Cash from Operating Activities growth rates for Adaptimmune Therapeutics PLC have been -38% over the past three years , -6% over the past five years .